OXFORD, England, January 13, 2015 /PRNewswire/ --
PharmaVentures is pleased to announce that it has acted as advisor to ESTEVE in their successful license agreement with MundiPharma Laboratories GmbH for E-58425, a first in class NSAID/Opioid API-API co-crystal for the treatment of pain.
ESTEVE is a privately-held pharmaceutical and chemical group that focuses on innovation and excellence in health. In a Phase II clinical study in post-operative pain, E-58425 demonstrated significant superior efficacy and safety compared to a standard of care.
Adrian Dawkes, Vice President, PharmaVentures Ltd. who was lead advisor to ESTEVE, commented: "We are delighted to have worked with ESTEVE in partnering E-58425 which represents a great step forward in the pain sector."
Fintan Walton, Chief Executive, PharmaVentures, Ltd added: "We continue to be recognised as a strong leader in healthcare deal making and this adds to a growing list of our recent successes."
For the past 23 years, PharmaVentures has acted as advisor to over 700 global pharmaceutical and biotechnology clients in transactions; covering licensing, mergers, acquisitions, divestments and joint venture activities for companies.
PharmaVentures is a premier transaction advisory firm; a world leader in partnering, M&A deals and strategic alliances. Our unrivalled bank of specialist experience, deal analytics and network of contacts among innovators and large pharma makes us uniquely placed to support your business in all aspects of deal making and strategic planning. PharmaVentures is well known for its deep insight into deal structures and its success for generating partnering interest.
Find out more http://www.pharmaventures.com
Our services include:
- M&A (divestments, mergers, acquisitions and strategic transactions)
- Strategy (commercialisation, deal strategy, due diligence, market entry)
- Valuation and Positioning (licensing, M&A, fund raising & expert testimonies)
- Licensing (in and out licensing)
- Expert Testimony (patent infringement, deal disagreements, taxation, determining damages)
Now entering its 23rd year, PharmaVentures is based in Oxford, UK, and employs 20 professionals and has associates in N. America, Latin America, Asia-Pacific.
For further information, contact:
Dr Fintan Walton
SOURCE PharmaVentures Ltd